Resonance Health Limited (ASX:RHT) disclosed a 42% revenue increase and a return to profitability in FY26 at its 2026 Annual General Meeting held on 19 November 2026, with Chairperson Aaron Brinkworth and Managing Director Andrew Harrison delivering addresses to shareholders.
Key Points
- Revenue grew by 42% in FY26, the company returned to profit, and profit converted to cash in every quarter of the year
- A $6 million placement was approved by the Board in October, described as oversubscribed and taken largely by institutional investors
- Two new directors appointed in April: Dr David Fuller and Michael Sistenich, with a majority of directors now independent
- Dr Travis Baroni stands for re-election, having served on the Board since 2016 and chairing the Audit & Risk Committee
FY26 Financial Performance and Cash Position
Chairperson Aaron Brinkworth stated that revenue grew by 42% in FY26, the company returned to profit, and that profit converted to cash in every quarter of the year. According to the filing, growth was funded from the company's own operations, and the company finished the year with more cash in the bank than debt. The filing also noted that the ASX confirmed the company no longer needs to lodge quarterly cash-flow reports, though Brinkworth stated shareholders would continue to receive updates at the half year, full year, through investor presentations, and via continuous disclosure obligations.
$6 Million Placement and Board Rationale
The Board approved a $6 million placement in October 2026, with the filing stating the book was oversubscribed and went largely to institutional investors. Brinkworth disclosed that the placement was approved to fund three programmes concurrently: new body-composition endpoints for obesity trials, new TrialsWest sites on the east coast, and the next stage of the liver fibrosis device. The filing states that without the placement, the company's cash flow would have funded the three programmes sequentially over several years. The Board and management collectively own approximately one fifth of the company, according to the filing.
Board Composition and Director Elections
The filing disclosed the appointment in April of two new directors: Dr David Fuller, described as a physician and pharmacist with more than thirty years in international drug development including clinical trials and regulatory approval in the United States and Europe, and Michael Sistenich, with more than twenty-five years in healthcare, life sciences and institutional investment. Both stand for election at the 2026 AGM. Dr Travis Baroni, who has served on the Board since 2016 and chairs the Audit & Risk Committee, stands for re-election. The filing also noted that Dr Martin Blake stepped down as Chairperson in November of the prior year.




Please wait processing your request...